<DOC>
	<DOC>NCT00002270</DOC>
	<brief_summary>To study the effectiveness of alpha interferon (IFN-A2b) and zidovudine (AZT) in treating progressive multifocal leukoencephalopathy (PML) as a complication of HIV-1 infection.</brief_summary>
	<brief_title>A Pilot Study of the Efficacy of Recombinant Alpha Interferon (IFN-A2b) and Zidovudine (AZT) in the Treatment of Progressive Multifocal Leukoencephalopathy (PML) Complicating HIV-1 Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Leukoencephalopathies</mesh_term>
	<mesh_term>Leukoencephalopathy, Progressive Multifocal</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Patients must have: HIV seropositivity by both ELISA and Western blot. Biopsy proven progressive multifocal leukoencephalopathy (PML). Exclusion Criteria Coexisting Condition: Patients with the following conditions or symptoms are excluded: Intolerant to interferon. Prior or concomitant central nervous system disease (CNS) such as toxoplasmosis, multiple sclerosis (MS), or neurosyphilis. Patients with the following are excluded: Intolerant to interferon. Prior or concomitant central nervous system disease (CNS) such as toxoplasmosis, multiple sclerosis (MS), or neurosyphilis. Prior Medication: Excluded: Patients receiving interferon for other reasons.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 1991</verification_date>
	<keyword>Leukoencephalopathy, Progressive Multifocal</keyword>
	<keyword>Interferon Alfa-2b</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
</DOC>